Richard T Sawyer1, Jerrold L Abraham, Elaine Daniloff, Lee S Newman. 1. Division of Environmental and Occupational Health Sciences, Robert Hollis Laboratory of Environmental and Occupational Health Sciences, Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA. sawyerr@niaid.nih.gov
Abstract
OBJECTIVE: We hypothesized that beryllium (Be) might persist in lung granulomas in patients with chronic beryllium disease (CBD). METHODS: A total of 33 Be-exposed ceramics workers underwent transbronchial biopsy. They were classified based on histopathology and Be-lymphocyte proliferation test as CBD or other categories. Lung tissue sections were analyzed using secondary ion mass spectroscopy. RESULTS: Be was detected in the lungs of all Be-exposed groups. Be levels were increased within the granulomas of patients with CBD compared with the Be levels outside granulomas. Notably, Be was detectable in the lungs of CBD patients who had ceased exposure to Be an average of 9 years previously. CONCLUSIONS: Be was detected in the lungs of all Be-exposed subjects, with the highest levels of persistent Be inside CBD lung granulomas. Be antigen persistence may help explain the chronicity of this granulomatous disorder.
OBJECTIVE: We hypothesized that beryllium (Be) might persist in lung granulomas in patients with chronic beryllium disease (CBD). METHODS: A total of 33 Be-exposed ceramics workers underwent transbronchial biopsy. They were classified based on histopathology and Be-lymphocyte proliferation test as CBD or other categories. Lung tissue sections were analyzed using secondary ion mass spectroscopy. RESULTS:Be was detected in the lungs of all Be-exposed groups. Be levels were increased within the granulomas of patients with CBD compared with the Be levels outside granulomas. Notably, Be was detectable in the lungs of CBD patients who had ceased exposure to Be an average of 9 years previously. CONCLUSIONS:Be was detected in the lungs of all Be-exposed subjects, with the highest levels of persistent Be inside CBD lung granulomas. Be antigen persistence may help explain the chronicity of this granulomatous disorder.
Authors: Brent E Palmer; Douglas G Mack; Allison K Martin; May Gillespie; Margaret M Mroz; Lisa A Maier; Andrew P Fontenot Journal: J Immunol Date: 2008-02-15 Impact factor: 5.422
Authors: Richard T Sawyer; Andrew P Fontenot; Tristan A Barnes; Charles E Parsons; Brian C Tooker; Lisa A Maier; May M Gillespie; E Brigitte Gottschall; Lori Silveira; James Hagman; Lee S Newman Journal: Am J Respir Cell Mol Biol Date: 2006-09-15 Impact factor: 6.914
Authors: Michael T Falta; Jeremy C Crawford; Alex N Tinega; Laurie G Landry; Frances Crawford; Douglas G Mack; Allison K Martin; Shaikh M Atif; Li Li; Radleigh G Santos; Maki Nakayama; John W Kappler; Lisa A Maier; Paul G Thomas; Clemencia Pinilla; Andrew P Fontenot Journal: J Clin Invest Date: 2021-05-03 Impact factor: 14.808
Authors: Shaikh M Atif; Douglas G Mack; Amy S McKee; Javier Rangel-Moreno; Allison K Martin; Andrew Getahun; Lisa A Maier; John C Cambier; Rubin Tuder; Andrew P Fontenot Journal: JCI Insight Date: 2019-05-16
Authors: Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day Journal: Am J Respir Cell Mol Biol Date: 2009-11-09 Impact factor: 6.914
Authors: Douglas G Mack; Allison K Lanham; Brent E Palmer; Lisa A Maier; Tania H Watts; Andrew P Fontenot Journal: J Immunol Date: 2008-09-15 Impact factor: 5.422
Authors: Dave R Dobis; Richard T Sawyer; May M Gillespie; Jie Huang; Lee S Newman; Lisa A Maier; Brian J Day Journal: Am J Respir Crit Care Med Date: 2008-01-24 Impact factor: 21.405
Authors: Kristin J Cummings; Aleksandr B Stefaniak; M Abbas Virji; Kathleen Kreiss Journal: Environ Health Perspect Date: 2009-04-28 Impact factor: 9.031